Viyash Scientific Limited – Investor Presentation Summary

Key Operational Highlights

  • Revenue from operations reached ₹9,464 Mn in Q1 FY27, representing 19.5% YoY growth
  • Company operates 16 world-class manufacturing facilities across global locations
  • Maintains global presence across 150+ countries serving 250+ global customers
  • R&D capabilities include 250+ scientists and 175+ patents filed

Key drivers of operational performance: Robust execution, improving operating leverage, well-defined growth strategy, and reduction in finance costs due to debt reduction

Segment-wise Performance

  • Formulations segment: ₹5,547 Mn (33% YoY growth)
  • Europe: ₹1,847 Mn (13% YoY growth)
  • Emerging Markets: ₹2,008 Mn (36% YoY growth)
  • India: ₹430 Mn (63% YoY growth)
  • USA: ₹1,262 Mn (60% YoY growth)
  • APIs segment: ₹3,833 Mn (4% YoY growth)
  • Other Sales: ₹75 Mn

Explanation of significant changes in segment performance: Formulations growth driven by strong performance across all geographic regions, particularly USA and India showing exceptional growth rates

Financial Highlights

Revenue: ₹9,464 Mn

EBITDA: ₹2,047 Mn

PAT: ₹793 Mn

EBITDA Margin: 21.6%

PAT Margin: 8.4%

YoY/QoQ comparison: Revenue grew 19.5% YoY and 2.9% QoQ; EBITDA grew 59.2% YoY and 2.3% QoQ; PAT grew 114.9% YoY and 19.4% QoQ

Drivers of financial performance: Higher revenue growth, gross margin expansion to 54.1% from 51.9% YoY, reduction in employee benefit expenses as percentage of revenue, lower finance costs due to debt reduction

Key Risks: Not explicitly disclosed in the presentation

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not explicitly broken down in percentage terms, but geographic revenue distribution shows:

  • Europe: ₹1,847 Mn
  • Emerging Markets: ₹2,008 Mn
  • India: ₹430 Mn
  • USA: ₹1,262 Mn

Regional Breakdown: Revenue distribution across major markets provided with growth rates for each region

Balance Sheet Snapshot

Net Debt/Equity: Not specified

Reserves: Not specified

Current Assets/Liabilities: Not specified

Working Capital/Leverage Metrics: Not specified

Financial Health Insights: Reduction in finance cost on account of reduction in debt mentioned as positive factor

Capex & Cash Flow Health

Capital Expenditure: Not specified

Free Cash Flow: Not specified

Operating Cash Flow: Not specified

Net Debt Movement: Reduction in debt mentioned as contributing to lower finance costs

Investment Rationale: Strategic investments in line with long-term strategy for sustainable growth, including manufacturing expansion and market expansion

Strategic & R&D Initiatives

Investments in Innovation: 250+ scientists across multiple R&D centers; API R&D capabilities include scalable complex APIs including high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules; Formulation R&D for both human and animal health

Expected impact on growth: Acquisition of Bio For Life provides access to large companion animal market in Italy with 85-90 products that can be extended to other core markets

Strategic Rationale: Expanding into high-growth markets through acquisition strategy; building integrated pharmaceutical platform across animal and human health; focused on companion animal segment expansion

Industry Trends & Business Environment

Macro/Industry Trends: Not explicitly discussed in the presentation

Impact on Company: Not specified

Management Commentary & Growth Outlook

Strategic Outlook: "Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth" - Dr Hari Babu Bodepudi, Managing Director and Group CEO

FY Guidance: Not explicitly provided

Market Share Targets: Not specified

Risks and Opportunities: Not specifically highlighted

Long Term Strategy

Animal formulations: Companion Animals - New product development, Market expansion, Manufacturing expansion, M&A; Farm Animals - Portfolio completion, Geography extension

API & CDMO: Portfolio expansion, Day 1 launch, Complex CDMO

Human formulations: API integrated play, Complex products including oncology